ANI Pharmaceuticals (ANIP) SVP logs stock grant and tax withholding in Form 4

Rhea-AI Filing Summary

ANI Pharmaceuticals senior vice president of generics, Ori Gutwerg, reported two equity-related transactions in common stock. On February 26, 2026, he acquired 12,969 shares at $77.15 per share as a grant or award, bringing his direct holdings to 89,063 shares. According to a footnote, this restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.

On February 28, 2026, 2,221 shares were disposed of at $73.90 per share in a tax-withholding disposition related to the vesting of 4,342 previously granted restricted shares, leaving Gutwerg with 86,842 directly owned shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Gutwerg Ori

Role SVP, GENERICS

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,221	$73.90	$164K
Grant/Award	Common Stock	12,969	$77.15	$1.00M

Holdings After Transaction: Common Stock — 86,842 shares (Direct)

Footnotes (1)

1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gutwerg Ori

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GENERICS

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		12,969	A	$77.15	89,063	D
Common Stock	02/28/2026		F(2)		2,221	D	$73.9	86,842	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Remarks:

	/s/ Ori Gutwerg, by attorney-in-fact Meredith W. Cook	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ANIP executive Ori Gutwerg report on this Form 4?

Ori Gutwerg reported one equity grant and one tax-withholding share disposition. He received 12,969 restricted common shares on February 26, 2026, then 2,221 shares were withheld on February 28, 2026, to cover taxes tied to vesting of 4,342 restricted shares.

How many ANI Pharmaceuticals (ANIP) shares does Ori Gutwerg own after these Form 4 transactions?

After the reported transactions, Ori Gutwerg directly owns 86,842 ANI Pharmaceuticals common shares. This figure reflects the 12,969-share grant on February 26, 2026, and the 2,221 shares withheld for taxes on February 28, 2026, as disclosed in the filing.

What are the vesting terms of Ori Gutwerg’s new restricted stock award at ANIP?

The restricted stock award of 12,969 shares vests in four equal annual installments. Vesting occurs on the first, second, third, and fourth anniversaries of February 26, 2026, meaning the award is spread evenly over four years, subject to those scheduled dates.

Why were 2,221 ANI Pharmaceuticals shares disposed of in Gutwerg’s Form 4?

The 2,221 shares were withheld for tax purposes in connection with restricted stock vesting. A footnote explains they relate to the vesting of 4,342 previously granted restricted shares, with the withholding treated as a tax-liability payment under Rule 16(b)-3.

Were Ori Gutwerg’s ANIP Form 4 transactions open-market buys or sells?

Neither transaction was an open-market trade. One entry is a grant or award acquisition of 12,969 restricted shares, and the other is a tax-withholding disposition of 2,221 shares tied to restricted stock vesting, rather than a discretionary market sale.

What prices are associated with the ANIP insider transactions reported by Ori Gutwerg?

The grant of 12,969 restricted shares is reported at a price of $77.15 per share. The tax-withholding disposition of 2,221 shares is reported at $73.90 per share, reflecting the valuation used for those non-open-market equity transactions.